20000397-54

IPOS copy - for reference only

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 47/12, 9/20, 9/48, C07D 261/04

A1

(11) International Publication Number: WO 99/36096

(43) International Publication Date: 22 July 1999 (22.07.99)

(21) International Application Number: PCT/US99/00748

(22) International Filing Date: 14 January 1999 (14.01.99)

(30) Priority Data:
60/071,712 16 January 1998 (16.01.98) US

(71) Applicant: DU PONT PHARMACEUTICALS COMPANY [US/US]; 974 Centre Road, WR–1ST18, Wilmington, DE 19807 (US).

(72) Inventors: BADAWY, Sherif, I.; Apartment D, 803 Cloister Road, Wilmington, DE 19809 (US). GILBERT, Donna, L.; 117 North Village Lane, Chadds Ford, PA 19317 (US).

(74) Agent: BLACK, Robert, W.; Du Pont Pharmaceuticals Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION

(57) Abstract

Provided is a pharmaceutical composition comprising a tablet or capsule containing a pharmacologically effective amount of a pharmaceutical compound, or a pharmaceutically acceptable salt thereof, having an amidine–based group and an optional ester group, a pharmaceutically acceptable solid carrier, and a pharmaceutically acceptable acid in an amount to modify the pH of the composition to substantially that of the compound at pH of maximum stability. Such a composition is prepared by adding water during formulation manufacture and contacting the compound during formulation manufacture with a pharmaceutically acceptable acid having a pH in a saturated aqueous solution substantially that of the compound at pH of maximum stability.